Next Article in Journal
Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization
Previous Article in Journal
Transformation of Cellulose via Two-Step Carbonization to Conducting Carbonaceous Particles and Their Outstanding Electrorheological Performance
Previous Article in Special Issue
GABAA Receptor Autoantibodies Decrease GABAergic Synaptic Transmission in the Hippocampal CA3 Network
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
IJMS
Volume 23
Issue 10
10.3390/ijms23105479
ijms-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells

by
Elham Poonaki
1,2,3,
Ann-Christin Nickel
4,
Mehdi Shafiee Ardestani
5,
Lars Rademacher
2,
Marilyn Kaul
2,
Evgeny Apartsin
6,7,
Sven G. Meuth
1,
Ali Gorji
8,9,
Christoph Janiak
2,* and
Ulf Dietrich Kahlert
3,*
1
Department of Neurology, Faculty of Medicine, Heinrich-Heine-University, 40225 Düsseldorf, Germany
2
Institut für Anorganische Chemie und Strukturchemie, Heinrich-Heine-University, 40204 Düsseldorf, Germany
3
Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Transplantation Surgery, Faculty of Medicine, Otto-von-Guericke-University, 39120 Magdeburg, Germany
4
Clinic for Neurosurgery, Heinrich-Heine-University, 40225 Düsseldorf, Germany
5
Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1416634793, Iran
6
Institute of Chemical Biology and Fundamental Medicine SB RAS, 630090 Novosibirsk, Russia
7
Laboratoire de Chimie de Coordination CNRS, 31400 Toulouse, France
8
Epilepsy Research Center, Department of Neurosurgery and Department of Neurology, Westfälische Wilhelms-Universität, 48149 Münster, Germany
9
Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran 9815733169, Iran
*
Authors to whom correspondence should be addressed.
Academic Editors: Rolf Heumann and Frank Schmitz
Int. J. Mol. Sci. 2022, 23(10), 5479; https://doi.org/10.3390/ijms23105479
Received: 7 April 2022 / Revised: 4 May 2022 / Accepted: 9 May 2022 / Published: 13 May 2022
(This article belongs to the Collection State-of-the-Art Molecular Neurobiology in Germany)
View Full-Text Download PDF
Browse Figures

Abstract

The failure of a long-lasting curative therapeutic benefit of currently applied chemotherapies against malignant cancers is suggested to be caused by the ineffectiveness of such interventions on cancer stem cells (CSCs). CD133/AC133 is a cell surface protein previously shown to have potential to identify CSCs in various tumors, including brain tumors. Moreover, an increase in the rate of cellular metabolism of glutamine and glucose are contributors to the fast cellular proliferation of some high-grade malignancies. Inhibition of glutaminolysis by utilizing pharmacological inhibitors of the enzyme glutaminase 1 (GLS1) can be an effective anti-CSC strategy. In this study, the clinical-stage GLS1 inhibitor Telaglenastat (CB-839) was loaded into PEGylated gold nanoparticles equipped with the covalently conjugated CD133 aptamer (Au-PEG-CD133-CB-839) and exposed to a collection of CD133-positive brain tumor models in vitro. Our results show that Au-PEG-CD133-CB-839 significantly decreased the viability of CD133-postive cancer cells in a dose-dependent manner, which was higher as compared to the effects of treatment of the cells with the individual components of the assembled nanodrug. Interestingly, the treatment effect was observed in glioblastoma stem cells modeling different transcriptomic subtypes of the disease. The presented platform is the fundament for subsequent target specificity characterization and in vivo application. View Full-Text
Keywords: cancer stem cells; nanomedicine; glutaminase; onco-metabolism; CD133 cancer stem cells; nanomedicine; glutaminase; onco-metabolism; CD133
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Poonaki, E.; Nickel, A.-C.; Shafiee Ardestani, M.; Rademacher, L.; Kaul, M.; Apartsin, E.; Meuth, S.G.; Gorji, A.; Janiak, C.; Kahlert, U.D. CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. Int. J. Mol. Sci. 2022, 23, 5479. https://doi.org/10.3390/ijms23105479

AMA Style

Poonaki E, Nickel A-C, Shafiee Ardestani M, Rademacher L, Kaul M, Apartsin E, Meuth SG, Gorji A, Janiak C, Kahlert UD. CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. International Journal of Molecular Sciences. 2022; 23(10):5479. https://doi.org/10.3390/ijms23105479

Chicago/Turabian Style

Poonaki, Elham, Ann-Christin Nickel, Mehdi Shafiee Ardestani, Lars Rademacher, Marilyn Kaul, Evgeny Apartsin, Sven G. Meuth, Ali Gorji, Christoph Janiak, and Ulf D. Kahlert. 2022. "CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells" International Journal of Molecular Sciences 23, no. 10: 5479. https://doi.org/10.3390/ijms23105479

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1

Author Biographies

Back to TopTop